The quest for novel targets breaking cancer therapeutic resistance has led to exciting efforts to leverage ferroptosis specifically in cancer cells, traditionally vulnerable to iron-dependent lipid peroxidation1. In a recent paper published in this venue, Mao et al.2 introduced mitochondrially localized dihydroorotate dehydrogenase (DHODH) as an enzyme mediating ferroptosis resistance in tumor cells by reducing mitochondrial ubiquinone (CoQ10), which in turn facilitates scavenging of oxygen radicals in mitochondrial membranes.